TransCode Therapeutics, Inc.: 5%+ holders

As of November 7, 2026, 5 holders' latest Schedule 13D or 13G filings report owning 5% or more of TransCode Therapeutics, Inc. The largest reported stake is CK Life Sciences Int'l., (Holdings) Inc.'s, at 83.9%. 14 filings are on record since August 14, 2025 (Schedule 13D/A, August 3, 2026).

YA II PN, Ltd. also filed stake reports on 13 other companies ↓

Sell to companies like TransCode Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Event date 2026-08-03 · Holder: CK Life Sciences Int'l., (Holdings) Inc. · Percent: 83.9% · Shares: 14,134,481 · SCHEDULE 13D/A
• Filing 2026-07-28 · Reporting person: Unleash Immuno Oncolytics, Inc. · Sole voting: 300,000 · Shared voting: 0 · Sole dispositive: 300,000 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-28
• Filing 2026-07-28 · Reporting person: Elena Rosa Braci · Sole voting: 186,236 · Shared voting: 0 · Sole dispositive: 186,236 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-28
• Filing 2026-07-28 · Reporting person: Daniel Eduardo Katzman · Sole voting: 155,611 · Shared voting: 0 · Sole dispositive: 155,611 · Shared dispositive: 0 · SCHEDULE 13G, 2026-07-28
• Filed 2026-07-27 · Holder: CK Life Sciences Int'l., (Holdings) Inc. · Percent: 83.9% · SCHEDULE 13D/A

TransCode Therapeutics, Inc. has 14 Schedule 13D or 13G filings on record since 2025-08-14. 5 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind TransCode Therapeutics, Inc. and the warning signs.

See TransCode Therapeutics, Inc.'s free Snapshot Watch TransCode Therapeutics, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on TransCode Therapeutics, Inc. and the records around it.

TransCode Therapeutics, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• YA II PN, Ltd. also filed stake reports on 13 other companies: Ives Ultra AI Opportunities Inc. (Oct 2026), Beneficient (Oct 2026), Optimi Health Corp. (Oct 2026)
• SABBY MANAGEMENT, LLC also filed stake reports on 15 other companies: Globavend Holdings Ltd (Jan 2026), Jiuzi Holdings, Inc. (Jan 2026), Tempest Therapeutics, Inc. (Jan 2026)
• Anson Funds Management LP also filed stake reports on 36 other companies: 22nd Century Group, Inc. (Aug 2026), Imperial Petroleum Inc. (Aug 2026), K Wave Media Ltd. (Aug 2026)

Want the whole picture on TransCode Therapeutics, Inc.?

Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC

A Full Report on TransCode Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on TransCode Therapeutics, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   16 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies TransCode Therapeutics, Inc. by CUSIP 89357L501 and gives its principal executive office as 6 Liberty Square, #2382, Boston, MA 02109 (SCHEDULE 13D/A, 2026-08-03).

Purpose of Transaction (Item 4)

CK Life Sciences Int'l., (Holdings) Inc.

Item 4 of Schedule 13D is hereby amended by adding the below disclosure following the last paragraph of Item 4: On August 3, 2026, upon obtaining the consent of a majority of the holders of the Preferred Stock, and the approval of the Company's Board of Directors, the Company filed a Second Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock (the "Second Amended and Restated Certificate of Designation") with the Secretary of State of the State of Delaware. The Second Amended and Restated Certificate of Designation amended Section 6.3.3 of the Amended and Restated Certificate of Designation of Preferences, Rights and Limitations of Series A Non-Voting Convertible Preferred Stock and Series B Non-Voting Convertible Preferred Stock ("Amended and Restated Certificate of Designation") to remove the requirement of 60 days' notice to change and/or waive the beneficial ownership limitation set forth in the Amended and Restated Certificate of Designation. The Second Amended and Restated Certificate of Designation effected no other changes to the Amended and Restated Certificate of Designation other than the foregoing, and no additional securities were issued or sold in connection with the filing. The foregoing description of the Second Amended and Restated Certificate of Designation does not purport to be complete and is qualified in its …The first part of Item 4 of the SCHEDULE 13D/A filed 2026-08-03; the filing has the rest

Timeline

Swipe the table sideways to see every column.

Questions about who owns TransCode Therapeutics, Inc.

Who owns TransCode Therapeutics, Inc.?

On this page, 5 holders' latest ownership filings report 5% or more of TransCode Therapeutics, Inc.: CK Life Sciences Int'l., (Holdings) Inc. (83.9%, Schedule 13D/A, filed 2026-08-03), Unleash Immuno Oncolytics, Inc. (9.94%, Schedule 13G, filed 2026-07-28), YA II PN, Ltd. (9.9%, Schedule 13G, filed 2026-04-20), Elena Rosa Braci (6.17%, Schedule 13G, filed 2026-07-28) and Daniel Eduardo Katzman (5.16%, Schedule 13G, filed 2026-07-28).

Who are the largest shareholders of TransCode Therapeutics, Inc.?

By the share each holder's latest filing reports, the largest holders of TransCode Therapeutics, Inc. on this page are CK Life Sciences Int'l., (Holdings) Inc. (83.9%), Unleash Immuno Oncolytics, Inc. (9.94%) and YA II PN, Ltd. (9.9%).

When did CK Life Sciences Int'l., (Holdings) Inc. buy into TransCode Therapeutics, Inc.?

The filings give report dates, not purchase dates. The earliest filing from CK Life Sciences Int'l., (Holdings) Inc. on this page is the Schedule 13D, filed 2025-10-16, reporting 9.1%; its latest, Schedule 13D/A filed 2026-08-03, reports 83.9%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 14 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for TransCode Therapeutics, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for TransCode Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when TransCode Therapeutics, Inc. is mentioned again
• Find former TransCode Therapeutics, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes